On November 21, 2025, the Phase IIIa clinical trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cell) jointly developed by Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) and its subsidiaries Chengdu XinNuoming Biotechnology Co., Ltd. and Lanzhou Bailing Biotechnology Co., Ltd. successfully completed the enrollment of all subjects, marking a key progress of this project in the clinical research stage and a solid step forward for the final market approval of the vaccine.
Overview of Clinical Trials
This Phase IIIa clinical trial adopts a randomized, blinded, positive-controlled design, aiming to further evaluate the efficacy and safety of the vaccine and provide sufficient and powerful scientific evidence for the final market approval of the vaccine. The trial was carried out simultaneously in clinical research centers in Sichuan and Chongqing. Thanks to the full support of clinical research institutions in the two regions, governments and health commissions of districts and counties where the trial sites are located, rapid enrollment was achieved, racing against the upcoming high influenza season and is expected to provide a new prevention and control method for the upcoming influenza season.
Vaccine Background
Influenza is an acute respiratory infectious disease caused by influenza virus, which is highly contagious, spreads rapidly and widely, can lead to high morbidity and significant mortality, and poses a major threat to global public health. Vaccination is one of the most effective methods to prevent influenza. The Quadrivalent Influenza Virus Split Vaccine (MDCK Cell) developed by Olymvax is intended for people aged 6 months and above to prevent influenza caused by influenza virus subtypes related to the vaccine. This vaccine is produced with advanced cell matrix technology. Compared with traditional production processes, it has many advantages such as higher production yield, more stable product quality and lower production cost. It is expected to fill the gap in the domestic cell-based influenza vaccine market, provide a better and more efficient vaccine option for China’s influenza prevention and control work, and further improve the overall supply capacity and prevention and control level of influenza vaccines in China.
Company Impact
The smooth advancement of the Phase III clinical trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cell) is of great significance to Olymvax. It not only helps to further improve the Company’s R&D pipeline and enrich the Company’s product layout, laying a more solid foundation for the Company’s high-quality and sustainable development, but also a strong reflection of the Company’s R&D strength.
About Olymvax
Chengdu Olymvax Biopharmaceuticals Inc. is a high-tech enterprise focusing on the R&D, production and sales of human vaccines. Since its establishment, the Company has always adhered to the concept of “Innovation, Quality, Responsibility”, taken advanced biotechnology as the core driving force, and committed to contributing to the global public health cause. In the field of vaccine R&D, Olymvax continues to explore and innovate, and has built a rich and forward-looking R&D pipeline covering R&D projects of vaccines for various major infectious diseases. With the continuous advancement of clinical trials, we believe that Olymvax’s Quadrivalent Influenza Virus Split Vaccine (MDCK Cell) is expected to be approved for marketing at an early date, providing a new powerful weapon for influenza prevention and control, contributing more “Olymvax Power” to the global public health cause, protecting public health, and helping to build a more complete global public health defense line.